DrugPatentWatch Database Preview

Ripretinib - Generic Drug Details

« Back to Dashboard

What are the generic sources for ripretinib and what is the scope of patent protection?

Ripretinib is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ripretinib has twenty-nine patent family members in eleven countries.

Summary for ripretinib

International Patents:	29
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	3
Patent Applications:	17
What excipients (inactive ingredients) are in ripretinib?	ripretinib excipients list
DailyMed Link:	ripretinib at DailyMed

Recent Clinical Trials for ripretinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Deciphera Pharmaceuticals LLC	Phase 1
Zai Lab (Shanghai) Co., Ltd.	Phase 2

See all ripretinib clinical trials

US Patents and Regulatory Information for ripretinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes			Y	Y

International Patents for ripretinib

Country	Patent Number	Estimated Expiration
South Korea	20090069296
Japan	5265550
Brazil	PI0716981
Eurasian Patent Organization	200970279